Nightstar Therapeutics PLC Sponsored ADR
(NASDAQ : NITE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.95%42.960.9%$1172.19m
LLYEli Lilly and Company
1.04%124.001.0%$1160.63m
JNJJohnson & Johnson
0.86%136.590.6%$960.96m
MRKMerck & Co., Inc.
1.12%80.720.6%$933.10m
BMYBristol-Myers Squibb Company
1.70%50.981.4%$779.97m
ABBVAbbVie, Inc.
1.60%80.012.2%$667.49m
AZNAstraZeneca PLC Sponsored ADR
1.27%40.951.3%$191.16m
NVSNovartis AG Sponsored ADR
0.30%90.780.2%$183.03m
GSKGlaxoSmithKline plc Sponsored ADR
0.03%40.550.2%$135.60m
NVONovo Nordisk A/S Sponsored ADR Class B
0.28%49.800.1%$67.28m
SNYSanofi Sponsored ADR
-0.36%41.180.2%$36.78m
LCILannett Company, Inc.
0.64%9.4136.7%$16.84m
AKTXAkari Therapeutics Plc Sponsored ADR
-2.70%1.801.7%$0.06m
EPIXESSA Pharma Inc
1.96%3.640.1%$0.04m

Company Profile

Nightstar Therapeutics PLC is a clinical-stage gene therapy company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.